SOPHIA ANTIPOLIS CEDEX, FRANCE--(Marketwire - Nov 9, 2012) - Nicox S.A. (EURONEXT PARIS: COX) is attending the American Academy of
Ophthalmology (AAO) & Asia Pacific Academy of Ophthalmology (APAO) 2012
Joint
Meeting, taking place from November 10 to 13 in Chicago, Illinois, United
States
(US). Nicox can be found at booth number 2735.
Nicox's US operational team, including Jerry St. Peter, Executive Vice
President
(EVP) and General Manager of Nicox Inc, will present AdenoPlus™, a rapid
point-of-care diagnostic test that aids in the differential diagnosis of
acute
conjunctivitis. AdenoPlus™ was launched by Nicox in the US in October
2012
(see Nicox press release dated October 22, 2012).
Michele Garufi, Chairman and CEO, Gavin Spencer, EVP Corporate Development
and
Philippe Masquida, EVP, Managing Director of European & International
Operations
will also attend the meeting.
Nicox's goal is to become a new international player in the ophthalmic
market by
building a diversified portfolio of innovative therapies and diagnostic
tools.
...................................
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new international
player in the ophthalmic market by building a diversified portfolio of
innovative therapies and diagnostic tools. With a heritage of scientific,
business development and commercial expertise, strengthened by internal
research
capabilities, Nicox is focused on developing and marketing novel
pharmaceuticals
and diagnostics that can help people to enhance their sight. In the United
States, Nicox markets AdenoPlus™, a test for the differential diagnosis
of
acute conjunctivitis in-licensed from RPS®, to eyecare practitioners.
The Company's pipeline includes BOL-303259-X, a novel drug-candidate based
on
Nicox's proprietary nitric oxide (NO)-donating R&D platform, developed in
collaboration with Bausch + Lomb for the potential treatment of glaucoma
and
ocular hypertension. Further NO-donating compounds are under development in
non-ophthalmic indications, notably through partners, including Merck
(known as MSD
outside the United States and Canada) and Ferrer.
Nicox S.A. is headquartered in France and is listed on Euronext Paris
(Compartment C: Small Caps). For more information
please visit www.nicox.com.
...................................
Nicox S.A.
Les Taissounières | Bât HB4 | 1681 route des Dolines | BP313
| 06906 Sophia
Antipolis Cedex |
France
T: +33 (0)4 97 24 53 00 | F: +33 (0)4 97 24 53
99
www.nicox.com
Nicox attends 2012 AAO Meeting in Chicago:
http://hugin.info/143509/R/1656395/535518.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE
[HUG#1656395]